424B5 filed May 8, 2026 at 17:13 ET
Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share, with an option for an additional 581,199 shares. The offering is expected to raise approximately $107.5 million in net proceeds (or $123.7 million if the option is fully exercised), which will be used to fund late-stage clinical programs, US commercialization efforts, and working capital. The company reported $247 million in cash as of March 31, 2026, and the offering extends its runway into the first half of 2028.